主页 > 医学前沿 >
【每日动态】每日生物医药动态报道 12月27日
有内部机密材料显示,强生早在2007年就知道泰诺工厂有严重问题
Confidential Witness: J&J Knew Tylenol Factory Was Failing in 2007
http://www.bnet.com/blog/drug-business/confidential-witness-j-j-knew-tylenol-factory-was-failing-in-2007/6897?tag=content;drawer-container
新药物或许可增强贫血病人产生红细胞的能力
Emerging Drug Class May Enhance Red Blood Cell Production in Anemic Patients
http://www.sciencedaily.com/releases/2010/12/101222141725.htm
盈利性护理院很可能超出收费标准敲诈美国联邦老人保险计划
For-Profit Nursing Homes More Likely to Overbill Medicare, U.S. Study Says
http://www.bloomberg.com/news/2010-12-23/for-profit-nursing-homes-more-likely-to-overbill-medicare-u-s-study-says.html
创始人因患白血病去世,塞弗隆公司提名新CEO,
Cephalon Names Buchi as CEO After Founder Baldino's Death From Leukemia
http://www.bloomberg.com/news/2010-12-23/cephalon-names-buchi-as-ceo-after-founder-baldino-s-death-from-leukemia.html
2010年药厂司法诉讼费高达45亿美元
Pharma's 2010 legal settlements top $4.5 billion
http://www.fiercepharma.com/story/pharmas-2010-legal-settlements-top-45-billion/2010-12-23
医药行业再度大肆裁人,2010年突破50000人
Another year of cuts as pharma layoffs hit 50,000
药品召回接二连三,伤及不止强生一家
Recall after recall hit more than just J&J
http://www.fiercepharma.com/story/recall-after-recall-hit-more-just-jj/2010-12-23
泰瓦下月将面临诺华和其他厂家的仿制药上市与其MS药物竞争
Teva May Face Copaxone Copy From Novartis, Momenta as Soon as Next Month
砷制剂在动物实验中显示可用于治疗难治性肿瘤
http://news.dxy.cn/bbs/topic/19094975#19094975
Arsenic Agent Shuts Down Two Hard-to-Treat Cancers in Animal Experiments
http://www.sciencedaily.com/releases/2010/12/101222121502.htm
ScienceDaily (Dec. 24, 2010) — Researchers at the Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown University Medical Center, have found that an arsenic-based agent already FDA-approved for a type of leukemia may be helpful in another hard-to-treat cancer, Ewing's Sarcoma (ES). The research, based on animal studies, also suggests the drug might be beneficial in treating medulloblastoma, a highly malignant pediatric brain cancer.
In the Dec. 22 issue of the Journal of Clinical Investigation, the investigators describe how years of research has uncovered a common pathway in these tumors, known as hedgehog/GLI1. They further detail how they used an existing drug, arsenic trioxide (Trisenox?), to shut down that pathway in mice models of ES and medulloblastoma.
This pathway is also common in other cancers, such as colon, pancreatic, and basal cell skin cancer, among others, says the study's lead investigator, associate professor Aykut ?ren, M.D., of Georgetown Lombardi.
"The significance of our finding is that this FDA approved agent can be tested immediately in other cancer types. It is a perfect translational research project," he says. "This laboratory research has immediate clinical implications."
?ren adds that researchers are moving quickly to find an effective inhibitor of the hedgehodg/GL1 pathway because it is so powerful in cancer development. Hedgehog controls cell division in embryonic development, but when it is turned on, and out of control in adult cells, cancer results. Because of that, there are a number of clinical trials underway testing new compounds that inhibit this pathway at the surface membrane of cancer cells, he says.
The compound they tested, however, inhibits the pathway in the nucleus, so it may be effective in cancers that have pathway activation downstream of the membrane molecules, ?ren says. "Many of the current clinical trials involve agents that act at the membrane. Ewing sarcoma and colon cancer will not benefit from that approach. Furthermore, medulloblastoma patients treated with hedgehog inhibitors are developing resistance at the membrane level. Therefore, clinical trials can evaluate alternative therapies for patients whose treatment fails with current hedgehog inhibitors," he says.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-12-27 00:02
医学,生命科学网